Previous Close | 43.35 |
Open | 43.10 |
Bid | 49.85 |
Ask | 53.85 |
Strike | 190.00 |
Expire Date | 2025-01-17 |
Day's Range | 43.10 - 43.35 |
Contract Range | N/A |
Volume | |
Open Interest | N/A |
As demand for novel IBD treatments rises, investment in this dynamic sector could be rewarding. Some of the key players in the market are AbbVie (ABBV), J&J (JNJ), Lilly (LLY) and Pfizer (PFE).
AbbVie (NYSE: ABBV) announced today topline results from the single-arm Phase 2 LUMINOSITY trial evaluating telisotuzumab-vedotin (Teliso-V) in patients with c-Met protein overexpression, epidermal growth factor receptor (EGFR) wild type, advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC). The results demonstrated a compelling overall response rate per independent central review (ICR) of 35 percent and 23 percent across c-Met High and c-Met Intermediate patients respectively.
AbbVie Inc. ( NYSE:ABBV ) has announced that it will be increasing its dividend from last year's comparable payment on...